TD Private Client Wealth LLC Makes New $291,000 Investment in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

TD Private Client Wealth LLC acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,346 shares of the specialty pharmaceutical company's stock, valued at approximately $291,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Quadrant Capital Group LLC raised its holdings in Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after buying an additional 101 shares during the period. Elequin Capital LP grew its stake in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after buying an additional 183 shares during the last quarter. CoreFirst Bank & Trust acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth approximately $28,000. Allianz SE bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $29,000. Finally, Parallel Advisors LLC lifted its stake in shares of Jazz Pharmaceuticals by 85.6% in the 1st quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock worth $32,000 after acquiring an additional 119 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Robert W. Baird cut their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 11th. Morgan Stanley dropped their price target on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Piper Sandler reissued an "overweight" rating and issued a $147.00 price target (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Finally, Wall Street Zen cut shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $184.00.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ traded down $2.21 during trading hours on Friday, reaching $110.27. 404,731 shares of the company's stock were exchanged, compared to its average volume of 613,577. The company has a current ratio of 3.38, a quick ratio of 2.97 and a debt-to-equity ratio of 1.28. The stock has a market cap of $6.67 billion, a PE ratio of 6.68, a price-to-earnings-growth ratio of 4.85 and a beta of 0.32. The firm has a fifty day moving average of $108.32 and a 200-day moving average of $118.64. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The company had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. During the same quarter last year, the company earned $2.68 EPS. The firm's quarterly revenue was down .5% on a year-over-year basis. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $116.35, for a total value of $116,350.00. Following the transaction, the chief executive officer directly owned 439,307 shares in the company, valued at approximately $51,113,369.45. This trade represents a 0.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Seamus Mulligan purchased 100,000 shares of the firm's stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the acquisition, the director owned 100,000 shares of the company's stock, valued at $9,826,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 2,500 shares of company stock valued at $277,930 in the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.